Abstract
Chronic myeloid leukaemia (CML) can be considered as a paradigm for neoplasias that evolve through a multi-step process. CML is also one of the best examples of a disease that can be targeted by molecular therapy; however, the success of new 'designer drugs' is largely restricted to the chronic phase of the disease. If not cured at this stage, CML invariably progresses and transforms into an acute-type leukaemia undergoing a 'blast crisis'. The causes of this transformation are still poorly understood. What mechanisms underlie this progression, and are they shared by other common cancers?
| Original language | English |
|---|---|
| Pages (from-to) | 441-53 |
| Number of pages | 13 |
| Journal | Nature Reviews Cancer |
| Volume | 7 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 2007 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Animals
- Blast Crisis
- Cell Differentiation
- Disease Progression
- Fusion Proteins, bcr-abl/physiology
- Gene Expression Profiling
- Genes, Tumor Suppressor/physiology
- Genomic Instability
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Models, Biological
- Neoplasms/pathology
Fingerprint
Dive into the research topics of 'Chronic myeloid leukaemia as a model of disease evolution in human cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver